Skip to content

EGCG Improves Acne by Modulating Molecular Targets

Epigallocatechin-3-Gallate Improves Acne in Humans by Modulating Intracellular Molecular Targets and Inhibiting P. Acnes

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01687556
Acronym
EGCG
Enrollment
35
Registered
2012-09-19
Start date
2005-07-31
Completion date
2006-06-30
Last updated
2012-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne Vulgaris

Keywords

EGCG, green tea

Brief summary

Epigallocatechin-3-gallate (EGCG) may improve acne vulgaris * major polyphenolic constituent in green tea * known as potent anti-carcinogenic, anti-inflammatory, anti-proliferative, and antimicrobial activities * lipid-lowering and antiandrogenic properties was reported * EGCG can improve acne vulgaris via one of the above mentioned actions.

Detailed description

Acne vulgaris is one of the most prevalent skin disorders of sebaceous follicles, affecting more than 85% of adolescents in United States. Acne can persist throughout the adulthood, and even a mild form of acne might progress to permanent scarring on the face, chest and back, thereby causing significant physical and psychosocial morbidities. Acne is a multifactorial disease of which etiology has not been fully elucidated, although considerable progress has been made in understanding its pathogenesis during last decade. The major pathogenic features of acne include abnormal ductal keratinization, sebum overproduction, Propionibacterium acnes, and inflammation. Common acne medications such as topical retinoids, antibiotics and isotretinoin are associated with irritation and incomplete responses, increased bacterial resistance or untoward side events, respectively. Thus there is a continuing need for a novel, effective agent targeting different aspects of acne pathogenesis, with minimal side effects. In the recent decade, epigallocatechin-3-gallate (EGCG), the major polyphenolic constituent in green tea, has attracted much interest on account of its potent anti-carcinogenic, anti-inflammatory, anti-proliferative, and antimicrobial activities. Preclinical, observational, and clinical trial data have indicated that EGCG can inhibit tumor initiation, promotion, progression, and angiogenesis. EGCG also suppresses neutrophil chemotaxis, and has been suggested to improve many diseases that have inflammatory components such as diabetes, kidney injuries, arthritis, allergies, dental caries, cardiovascular, gastrointestinal, and neurodegenerative diseases. In skin, EGCG has been investigated mainly in light of antioxidative, immunopotentiating and anticarcinogenic properties against chemicals or ultraviolet irradiation. Moreover, EGCG has lipid-lowering and antiandrogenic properties, and can downregulate peroxisome proliferator-activated receptor-γ expression. Based on these observations, it can be inferred that EGCG might be effective in the treatment of acne.

Interventions

OTHERtopical EGCG application on acne

two times application of topical EGCG on acne lesion

Sponsors

Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
15 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* age of at least 15 years * clinical diagnosis of mild to moderate acne vulgaris

Exclusion criteria

* known pregnancy or lactation * any medical illness that might influence the results of the study, * a previous history of oral acne medication or surgical procedures including laser treatment within 6 month and topical medication within 4 weeks of study enrollment.

Design outcomes

Primary

MeasureTime frameDescription
Assessment of acne severity8 week after baselineLesion counts of non-inflammatory lesions (closed comedone, open comedone) and severity measured by Reeds revised scale

Secondary

MeasureTime frame
2-mm punch biopsy of acne lesion on the EGCG-treated sides8 week after baseline
Standardized clinical photographs8 week after baseline

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026